Flavopiridol in Treating Patients With Recurrent Prostate Cancer
|ClinicalTrials.gov Identifier: NCT00003256|
Recruitment Status : Completed
First Posted : August 2, 2004
Last Update Posted : February 11, 2013
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: alvocidib||Phase 2|
I. Evaluate the clinical effectiveness of flavopiridol in patients with metastatic androgen independent adenocarcinoma of the prostate.
II. Assess the toxic effects of flavopiridol in this patient population.
Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation. Patients are followed every 3 months until death.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial of Flavopiridol in Patients With Metastatic Androgen Independent Prostate Cancer|
|Study Start Date :||May 1998|
|Actual Primary Completion Date :||July 2002|
|Actual Study Completion Date :||April 2004|
Experimental: Arm I
Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003256
|United States, California|
|Beckman Research Institute, City of Hope|
|Duarte, California, United States, 91010|
|University of California Davis Cancer Center|
|Sacramento, California, United States, 95817|
|United States, Massachusetts|
|Dana-Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|United States, Wisconsin|
|University of Wisconsin Comprehensive Cancer Center|
|Madison, Wisconsin, United States, 53792|
|Study Chair:||George Wilding, MD||University of Wisconsin, Madison|